SavedAdd your journal

Journals / Erciyes Medical Journal / 2018 / Cilt: 40 - Sayı: 1

Effectiveness and Safety of Clonazepam, Pregabalin, and Alpha Lipoic Acid for the Treatment of Burning Mouth Syndrome

Salih Levent ÇINAR
Demet KARTAL
Taha PERGEL
MURAT BORLU
Pages
35–38
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Systemic clonazepam and pregabalin are viable options for the treatment of burning mouth syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Burning mouth syndrome is characterized by pain in the oral mucosa with no visible organic pathology.
📊
Key Findings & Data:Clonazepam (2 mg/day) was administered to the patients in the first group, pregabalin (150 mg/day) to those in the second group, and alpha lipoic acid (600 mg/day) to those in the third group.
💡
Conclusion & Impact:Conclusion: Systemic clonazepam and pregabalin are viable options for the treatment of burning mouth syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Burning mouth syndrome is characterized by pain in the oral mucosa with no visible organic pathology. Few treatment options are available; however, none of them are gold-standard. Here we evaluated the effectiveness and safety of clonazepam, pregabalin, and alpha lipoic acid for treating burning mouth syndrome. Materials and Methods: Patients were divided into three groups. Clonazepam (2 mg/day) was administered to the patients in the first group, pregabalin (150 mg/day) to those in the second group, and alpha lipoic acid (600 mg/day) to those in the third group. Each group consisted of 30 patients. The intensity of oral pain in each group was measured before and at the end of the treatment (fourth month) using the visual analog scale. The study was carried on for four months. Results: Significant improvement was observed in the clonazepam and pregabalin groups; no effects were observed in the alpha lipoic acid group. No serious side effects were noted in any of the patients. Conclusion: Systemic clonazepam and pregabalin are viable options for the treatment of burning mouth syndrome.

🔖

Cite This Article

ÇINAR, S. L., KARTAL, D., PERGEL, T., BORLU, M. (2018). Effectiveness and Safety of Clonazepam, Pregabalin, and Alpha Lipoic Acid for the Treatment of Burning Mouth Syndrome. Erciyes Medical Journal, Cilt: 40 - Sayı: 1, 35–38. https://ajindex.com/articles/223469

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. Oral Dis 2017 Mar 1 Maltsman-Tseikhin A, Moricca P, Niv D. Burning mouth syndrome: will better understanding yield better management? Pain Pract 2007; 7(2): 151–62. [CrossRef] Lamey PJ, Lewis MA. Oral medicine in practice: burning mouth syndrome. Br Dent J 1989; 167(6): 197–200. [CrossRef] Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain 2002; 99(1-2): 41-7. [CrossRef] Minguez-Sanz M-P, Salort-Llorca C, Silvestre-Donat F-J. Etiology of burning mouth syndrome: a review and update. Med Oral Patol Oral Cir Bucal 2011; 16(2): e144-8. [CrossRef] Palacios-Sánchez B, Moreno-López L-A, Cerero-Lapiedra R, LlamasMartínez S, Esparza-Gómez G. Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial. Med Oral Patol Oral Cir Bucal 2015; 20(4): e435-40. [CrossRef] Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy. Pain Pract 2014; 14(2): 167–84. [CrossRef] Rodríguez de Rivera Campillo E, López-López J, Chimenos-Küstner E. Response to topical clonazepam in patients with burning mouth syndrome: a clinical study. Bull Group Int Rech Sci Stomatol Odontol 2010; 49(1): 19–29. Fornasari D. Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther 2017; 6(S1): 25–33. [CrossRef] Ali A, Bates JF, Reynolds AJ, Walker DM. The burning mouth sensation related to the wearing of acrylic dentures: an investigation. Br Dent J 1986; 161(12): 444–7. [CrossRef] Cavalcanti DR, Birman EG, Migliari DA, da Silveira FRX. Burning mouth syndrome: clinical profile of Brazilian patients and oral carriage of Candida species. Braz Dent J 2007; 18(4): 341–5. [CrossRef] Chimenos-Kustner E, Marques-Soares MS. Burning mouth and saliva. Med Oral 2002; 7(4): 244–53.
  2. Marino R, Capaccio P, Pignataro L, Spadari F. Burning mouth syndrome: the role of contact hypersensitivity. Oral Dis 2009; 15(4): 255–8. [CrossRef] Tourne LP, Fricton JR. Burning mouth syndrome. Critical review and proposed clinical management. Oral Surg Oral Med Oral Pathol 1992; 74(2): 158–67. [CrossRef] Lamb AB, Lamey PJ, Reeve PE. Burning mouth syndrome: psychological aspects. Br Dent J 1988; 165(7): 256–60. [CrossRef] Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A. Effect of lingual nerve block on burning mouth syndrome (